Jersey City, New Jersey, April 28, 2024 /PRNewswire/ — Celltrion united states of america today announced that it has signed an agreement with Express Scripts, one of the nation’s leading pharmacy benefit managers (PBMs) that negotiates health insurance plans for more than 100 million people.agreement is valid April 4, 2024 offers ZYMFENTRA Preferred Brand Access at Express Scripts National Preferred Formulary serving 21.9 million insureds. Express Scripts provides the ability to add her ZYMFENTRA to plan participants such as PBM health plans.™ (infliximab-dyyb) added to formulary.
“This agreement opens an important path to treatment for millions of people with chronic conditions.” Francine GalanteVice President of Market Access, Celltrion united states of america. “We continue to collaborate with healthcare professionals, patients, and physicians to further our mission of developing transformative treatments that meet the needs of patients living with chronic debilitating pain.”
Celltrion’s ZYMFENTRA, The first and only FDA-approved subcutaneous infliximab is commercially available in the United States.
The company communicates the value of FDA-approved treatments, including ZYMFENTRA, for patients with autoimmune diseases and works with national and local health plans, pharmacy benefit managers (PBMs) and group purchasing organizations to help secure widespread health coverage. We continue to collaborate with GPO. coverage.
About Celltrion united states of america
celltrion united states of america Celltrion is a US subsidiary founded in 2018. new jerseyCelltrion united states of america is committed to expanding access to innovative biologics to improve care for patients in the United States. Celltrion currently has five biosimilars approved by the US FDA: INFLECTRA®(infliximab-dyyb), TRUXIMA®(rituximab-abbs), Herzma®(trastuzumab-pkrb), Vegzelma®(bevacizumab-adcd), and eufrima®(adalimumab-aaty) and the new biologic ZYMFENTRA™.celltrion united states of america Celltrion will continue to leverage Celltrion’s unique heritage in biotechnology, superior supply chain and best-in-class distribution capabilities to improve access to high-quality biopharmaceuticals for patients in the United States. For more information, please visit www.celltrionusa.com/.
About Zyfentra™ (Infliximab-Dive)[1]
ZYMFENTRA is a prescription drug used as a subcutaneous injection (subcutaneous injection) by adults for maintenance therapy of: moderate to severe active ulcerative colitis after treatment with intravenous infusion (IV) with infliximab products; Moderately to severely active Crohn’s disease after treatment with intravenous (IV) infliximab products. ZYMFENTRA blocks the action of tumor necrosis factor alpha (TNF-alpha). Tumor necrosis factor alpha (TNF-alpha) is a protein that is overproduced in response to certain diseases and can cause the immune system to attack normal, healthy parts of the body.
ZYMFENTRA™ (infliximab-dyyb) was approved by the FDA through a Biologics License Application (BLA) under the Public Health Service Act 351(a) pathway (a “standalone” BLA). ZYMFENTRA is considered a new biologic with the first approved subcutaneous dosage form and is expected to receive patent protection for its dosage form by 2037 and for its route of administration by 2040.
|
[1] Zinfentra Prescribing Information |
contact address
sarah amundsen
[email protected]
+1 920-946-0918
Source Celltrion united states of america
